BV600022

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530498

CAS#: Unknown

Description: BV600022 is an osteoadsorptive bisphosphonate-ciprofloxacin conjugate. In vitro antimicrobial susceptibility testing of BV600022 against common osteomyelitis pathogens revealed an effective bactericidal profile and sustained release of the parent antibiotic over time. Efficacy and safety were demonstrated in an animal model of periprosthetic osteomyelitis, where a single dose of 10 mg/kg (15.6 µmol/kg) BV600022 reduced the bacterial load by 99% and demonstrated nearly an order of magnitude greater activity than the parent antibiotic ciprofloxacin (30 mg/kg, 90.6 µmol/kg) given in multiple doses.


Price and Availability

Size
Price

Size
Price

Size
Price

BV600022 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 530498
Name: BV600022
CAS#: Unknown
Chemical Formula: C26H28FN3O11P2
Exact Mass: 639.1183
Molecular Weight: 639.4659
Elemental Analysis: C, 48.84; H, 4.41; F, 2.97; N, 6.57; O, 27.52; P, 9.69


Synonym: BV600022; BV-600022; BV 600022.

IUPAC/Chemical Name: 1-cyclopropyl-7-(4-((4-(2,2-diphosphonoethyl)phenoxy)carbonyl)piperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

InChi Key: KWBYIXPNFABCJK-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H28FN3O11P2/c27-20-12-18-21(30(16-3-4-16)14-19(24(18)31)25(32)33)13-22(20)28-7-9-29(10-8-28)26(34)41-17-5-1-15(2-6-17)11-23(42(35,36)37)43(38,39)40/h1-2,5-6,12-14,16,23H,3-4,7-11H2,(H,32,33)(H2,35,36,37)(H2,38,39,40)

SMILES Code: O=C(N1CCN(C2=CC(N(C3CC3)C=C(C(O)=O)C4=O)=C4C=C2F)CC1)OC5=CC=C(CC(P(O)(O)=O)P(O)(O)=O)C=C5


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Osteomyelitis is a major problem worldwide, and is devastating due to the potential for limb-threatening sequelae and mortality. Osteomyelitis pathogens are bone-attached biofilms, making antibiotic delivery challenging. BV600022 incorporating a bisphosphonate and an antibiotic for bone-targeted delivery to treat osteomyelitis biofilm pathogens constitute a promising approach to providing high bone-antimicrobial potency while minimizing systemic exposure.


References

1: Sedghizadeh PP, Sun S, Junka AF, Richard E, Sadrerafi K, Mahabady S,
Bakhshalian N, Tjokro N, Bartoszewicz M, Oleksy M, Szymczyk P, Lundy MW,
Neighbors JD, Russell RG, McKenna CE, Ebetino FH. Design, synthesis, and
antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin
conjugate for the treatment of osteomyelitis biofilms. J Med Chem. 2017 Jan 25.
doi: 10.1021/acs.jmedchem.6b01615. [Epub ahead of print] PubMed PMID: 28121436.